Molecular Classification of Triple-Negative Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Sung Gwe | - |
dc.contributor.author | Kim, Seung Jun | - |
dc.contributor.author | Kim, Cheungyeul | - |
dc.contributor.author | Jeong, Joon | - |
dc.date.accessioned | 2021-09-03T20:49:02Z | - |
dc.date.available | 2021-09-03T20:49:02Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87726 | - |
dc.description.abstract | Tumor heterogeneity of triple-negative breast cancer (TNBC) has been the main barrier in conquering breast cancer. To dissect the molecular diversity of TNBC and discover therapeutic targets for TNBC, the molecular classification of TNBC is a prioritized issue in research area. Accordingly, recent studies have been successful in classifying TNBC into several distinct subtypes with specific biologic pathways. Despite the different methodologies used and varied number of final subtypes, these studies identically suggested that TNBC consists of four major subtypes: basal like, mesenchymal, lumina! androgen receptor, and immune-enriched. By reviewing these methods of classifications of TNBC, we highlight the unmet need to develop a molecular classifier suited for TNBC. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN BREAST CANCER SOC | - |
dc.subject | MESENCHYMAL-EPITHELIAL TRANSITION | - |
dc.subject | ADJUVANT CHEMOTHERAPY | - |
dc.subject | PLUS GEMCITABINE | - |
dc.subject | PHASE-III | - |
dc.subject | CARBOPLATIN | - |
dc.subject | IDENTIFICATION | - |
dc.subject | TRASTUZUMAB | - |
dc.subject | METASTASIS | - |
dc.subject | BIOMARKERS | - |
dc.subject | INHIBITOR | - |
dc.title | Molecular Classification of Triple-Negative Breast Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Cheungyeul | - |
dc.identifier.doi | 10.4048/jbc.2016.19.3.223 | - |
dc.identifier.scopusid | 2-s2.0-84992145869 | - |
dc.identifier.wosid | 000384386800001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF BREAST CANCER, v.19, no.3, pp.223 - 230 | - |
dc.relation.isPartOf | JOURNAL OF BREAST CANCER | - |
dc.citation.title | JOURNAL OF BREAST CANCER | - |
dc.citation.volume | 19 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 223 | - |
dc.citation.endPage | 230 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002147072 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | MESENCHYMAL-EPITHELIAL TRANSITION | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | PLUS GEMCITABINE | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | CARBOPLATIN | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | METASTASIS | - |
dc.subject.keywordPlus | BIOMARKERS | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | Gene expression | - |
dc.subject.keywordAuthor | Triple negative breast neoplasms | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.